Can Your Drug Gain An Edge in the TNF-Alpha Refractory Patient Segment of the Rheumatoid Arthritis Market?
Exploring Drug Attributes Needed to Maximize Patient Share

— A Webinar from Decision Resources

Based on our DecisionBase 2010 report, Rheumatoid Arthritis: Opportunity Awaits Therapies That Meet Physicians’ Efficacy Expectations in TNF-α Inhibitor-Refractory Patients, Decision Resources is offering an exclusive webinar entitled Can Your Drug Gain An Edge in the TNF-Alpha Refractory Patient Segment of the Rheumatoid Arthritis Market? Exploring Drug Attributes Needed to Maximize Patient Share. Because this webinar will feature major report findings, it is ONLY available to purchasers of this report.

Please contact us to learn how you can purchase this report and attend the webinar.

Rheumatoid arthritis affects more than 5 million people in the G7 (United States, France, Germany, Italy, Spain, United Kingdom and Japan) markets. Many highly effective disease-modifying antirheumatic drugs (DMARDs), including several biological DMARDs, are already available to treat rheumatoid arthritis and the market will become increasingly competitive following the launch of new agents from existing and novel drug classes. As a result, physicians are unwilling to accept agents with inferior efficacy and are becoming increasingly reluctant to quickly adopt new agents without longer-term safety data. However, owing to various safety and delivery shortcomings of current agents and because many patients remain unresponsive to treatment even after exhausting all treatment options, opportunity remains for emerging therapies that offer clinical profiles at least on par with those of marketed agents.

This webinar, presented by Decision Resources Analyst Joanna Kim, will answer the following questions:

• A growing number of drugs in development have demonstrated efficacy in TNF-alpha inhibitor refractory patients. What attributes will guide rheumatologists’ selection of agents in this increasingly crowded niche? Can certain attributes impede a drug’s uptake or provide a critical competitive edge?
• What attributes of Bristol-Myers Squibb’s Orencia (abatacept) and Roche/Biogen Idec/Chugai/Zenyaku Kogyo’s Rituxan, Roche’s MabThera (rituximab) provoke the greatest dissatisfaction among rheumatologists? Can recently launched and emerging agents, Roche/Chugai’s RoActemra/Actemra (tocilizumab), Genmab/GlaxoSmithKline's Arzerra (ofatumumab), Pfizer's CP-690550 and Rigel's fostamatinib disodium take advantage of their shortcomings?
• Efficacy is of paramount importance for rheumatoid arthritis patients who have failed multiple courses of therapy. How must emerging agents perform on key measures of efficacy such as relief of signs and symptoms, inhibition of disease progression and improvement in physical function, to compete with established biologics in the TNF-alpha refractory space?

Ms. Kim will conduct a live Q & A session after the presentation.

Registration

Can Your Drug Gain An Edge in the TNF-Alpha Refractory Patient Segment of the Rheumatoid Arthritis Market? Exploring Drug Attributes Needed to Maximize Patient Share

January 27, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this report and attend the webinar, please contact us using the information below.

Contact Us

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.